S&P 500   4,324.32 (+0.57%)
DOW   33,730.24 (+0.19%)
QQQ   362.68 (+1.30%)
AAPL   172.74 (+1.20%)
MSFT   319.12 (+1.75%)
META   309.45 (+1.81%)
GOOGL   133.85 (+1.16%)
AMZN   128.50 (+2.00%)
TSLA   254.39 (+3.25%)
NVDA   439.50 (+2.00%)
NIO   9.02 (+1.23%)
BABA   87.53 (+2.33%)
AMD   104.08 (+1.28%)
T   14.99 (-0.13%)
F   12.60 (+0.32%)
MU   67.95 (+4.22%)
CGC   0.79 (-2.42%)
GE   111.50 (-0.75%)
DIS   80.50 (+0.46%)
AMC   8.05 (+3.34%)
PFE   32.87 (+2.43%)
PYPL   58.96 (+1.34%)
NFLX   380.74 (+1.16%)
S&P 500   4,324.32 (+0.57%)
DOW   33,730.24 (+0.19%)
QQQ   362.68 (+1.30%)
AAPL   172.74 (+1.20%)
MSFT   319.12 (+1.75%)
META   309.45 (+1.81%)
GOOGL   133.85 (+1.16%)
AMZN   128.50 (+2.00%)
TSLA   254.39 (+3.25%)
NVDA   439.50 (+2.00%)
NIO   9.02 (+1.23%)
BABA   87.53 (+2.33%)
AMD   104.08 (+1.28%)
T   14.99 (-0.13%)
F   12.60 (+0.32%)
MU   67.95 (+4.22%)
CGC   0.79 (-2.42%)
GE   111.50 (-0.75%)
DIS   80.50 (+0.46%)
AMC   8.05 (+3.34%)
PFE   32.87 (+2.43%)
PYPL   58.96 (+1.34%)
NFLX   380.74 (+1.16%)
S&P 500   4,324.32 (+0.57%)
DOW   33,730.24 (+0.19%)
QQQ   362.68 (+1.30%)
AAPL   172.74 (+1.20%)
MSFT   319.12 (+1.75%)
META   309.45 (+1.81%)
GOOGL   133.85 (+1.16%)
AMZN   128.50 (+2.00%)
TSLA   254.39 (+3.25%)
NVDA   439.50 (+2.00%)
NIO   9.02 (+1.23%)
BABA   87.53 (+2.33%)
AMD   104.08 (+1.28%)
T   14.99 (-0.13%)
F   12.60 (+0.32%)
MU   67.95 (+4.22%)
CGC   0.79 (-2.42%)
GE   111.50 (-0.75%)
DIS   80.50 (+0.46%)
AMC   8.05 (+3.34%)
PFE   32.87 (+2.43%)
PYPL   58.96 (+1.34%)
NFLX   380.74 (+1.16%)
S&P 500   4,324.32 (+0.57%)
DOW   33,730.24 (+0.19%)
QQQ   362.68 (+1.30%)
AAPL   172.74 (+1.20%)
MSFT   319.12 (+1.75%)
META   309.45 (+1.81%)
GOOGL   133.85 (+1.16%)
AMZN   128.50 (+2.00%)
TSLA   254.39 (+3.25%)
NVDA   439.50 (+2.00%)
NIO   9.02 (+1.23%)
BABA   87.53 (+2.33%)
AMD   104.08 (+1.28%)
T   14.99 (-0.13%)
F   12.60 (+0.32%)
MU   67.95 (+4.22%)
CGC   0.79 (-2.42%)
GE   111.50 (-0.75%)
DIS   80.50 (+0.46%)
AMC   8.05 (+3.34%)
PFE   32.87 (+2.43%)
PYPL   58.96 (+1.34%)
NFLX   380.74 (+1.16%)
NASDAQ:GMAB

Genmab A/S (GMAB) Competitors

$35.71
+0.38 (+1.08%)
(As of 10:03 AM ET)
Compare
Today's Range
$35.56
$35.78
50-Day Range
$35.33
$42.25
52-Week Range
$31.86
$47.50
Volume
42,590 shs
Average Volume
468,092 shs
Market Capitalization
$23.59 billion
P/E Ratio
35.71
Dividend Yield
N/A
Price Target
$41.40

GMAB vs. ALNY, HZNP, BGNE, BMRN, VTRS, RDY, UTHR, LEGN, SRPT, and VRNA

Should you be buying Genmab A/S stock or one of its competitors? The main competitors of Genmab A/S include Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics Public (HZNP), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical preparations" industry.

Genmab A/S vs.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking.

Genmab A/S has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$1.04B21.22-$1.13B-$8.61-20.45
Genmab A/S$2.07B11.41$781.91M$1.0035.71

Alnylam Pharmaceuticals received 941 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 77.08% of users gave Alnylam Pharmaceuticals an outperform vote while only 59.24% of users gave Genmab A/S an outperform vote.

CompanyUnderperformOutperform
Alnylam PharmaceuticalsOutperform Votes
1066
77.08%
Underperform Votes
317
22.92%
Genmab A/SOutperform Votes
125
59.24%
Underperform Votes
86
40.76%

In the previous week, Genmab A/S had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 7 mentions for Genmab A/S and 6 mentions for Alnylam Pharmaceuticals. Genmab A/S's average media sentiment score of 1.39 beat Alnylam Pharmaceuticals' score of 0.91 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Genmab A/S
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alnylam Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

94.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 6.3% of Genmab A/S shares are held by institutional investors. 1.4% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Genmab A/S has a net margin of 28.78% compared to Genmab A/S's net margin of -85.95%. Alnylam Pharmaceuticals' return on equity of 16.93% beat Genmab A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals-85.95% -1,287.80% -30.66%
Genmab A/S 28.78%16.93%15.11%

Alnylam Pharmaceuticals currently has a consensus price target of $245.52, indicating a potential upside of 41.08%. Genmab A/S has a consensus price target of $756.80, indicating a potential upside of 2,042.09%. Given Alnylam Pharmaceuticals' higher possible upside, analysts clearly believe Genmab A/S is more favorable than Alnylam Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
0 Sell rating(s)
5 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
2.77
Genmab A/S
2 Sell rating(s)
7 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.27

Summary

Genmab A/S beats Alnylam Pharmaceuticals on 11 of the 18 factors compared between the two stocks.


Get Genmab A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GMAB vs. The Competition

MetricGenmab A/SPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$23.59B$5.70B$4.39B$6.36B
Dividend YieldN/A2.75%2.52%6.56%
P/E Ratio35.713.28101.8810.59
Price / Sales11.41145.142,966.6555.43
Price / Cash28.1422.1192.47103.11
Price / Book6.063.753.774.69
Net Income$781.91M$196.74M$122.26M$186.05M
7 Day Performance-1.03%0.88%1.00%0.67%
1 Month Performance-8.13%-8.04%-3.14%-5.36%
1 Year Performance11.84%7.52%11.48%6.70%

Genmab A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALNY
Alnylam Pharmaceuticals
2.7203 of 5 stars
$175.05
+2.5%
$247.40
+41.3%
-17.4%$21.88B$1.04B-20.332,002Analyst Report
Positive News
HZNP
Horizon Therapeutics Public
2.1924 of 5 stars
$115.74
+0.1%
$110.71
-4.3%
+81.2%$26.50B$3.63B61.892,115Analyst Upgrade
Short Interest ↓
BGNE
BeiGene
2.2863 of 5 stars
$185.56
-2.5%
$273.46
+47.4%
+29.3%$17.97B$1.42B-11.149,200Gap Down
BMRN
BioMarin Pharmaceutical
2.7557 of 5 stars
$88.06
+1.2%
$115.62
+31.3%
+4.0%$16.57B$2.10B169.353,082Analyst Report
Short Interest ↑
VTRS
Viatris
2.5541 of 5 stars
$9.72
flat
$12.67
+30.3%
+12.4%$11.66B$16.26B6.3537,000Positive News
RDY
Dr. Reddy's Laboratories
1.5858 of 5 stars
$65.93
-0.2%
$70.00
+6.2%
+26.3%$11.00B$261.11B19.0525,863
UTHR
United Therapeutics
2.9495 of 5 stars
$229.91
+2.6%
$296.44
+28.9%
+7.1%$10.79B$1.94B13.00985Positive News
LEGN
Legend Biotech
1.5886 of 5 stars
$64.36
+1.5%
$80.90
+25.7%
+66.8%$10.62B$117M0.001,390Positive News
SRPT
Sarepta Therapeutics
2.3907 of 5 stars
$119.41
+4.1%
$173.70
+45.5%
+12.4%$10.51B$933.01M-11.581,162Analyst Report
VRNA
Verona Pharma
1.7515 of 5 stars
$16.49
-0.4%
$32.60
+97.7%
+73.0%$10.48B$460,000.00-21.9935Positive News

Related Companies and Tools

This page (NASDAQ:GMAB) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -